Investing

GH Research : GHRS

GHRS

Stock Data

$28.55

$1.63 (6.06%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

GH Research PLC is a Dublin-based biopharmaceutical company focused on creating innovative treatments for psychiatric and neurological disorders. Their pioneering work revolves around 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies, particularly for individuals suffering from treatment-resistant depression (TRD). Their flagship product, GH001, is an inhalable therapy that has shown promise in early clinical trials. Additionally, GH Research is developing GH002 and GH003, targeting the same conditions with different delivery methods, both currently in the preclinical stage.

All GH Research Articles

1 Article

Ian Cooper | 7 minutes ago

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until…